Navigation Links
Alzheimer's Therapeutics Reviewed by NeuroPerspective
Date:9/6/2012

CARDIFF, Calif., Sept. 6, 2012 /PRNewswire/ -- NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. The focus is particularly timely, given the recent release of Phase III results for bapineuzumab and solaneuzumab, which serve as a reminder of how poorly the pharma industry has allocated its resources to date, both in terms of the premature embrace of the amyloid model, and the rush into hugely expensive Phase III programs without obtaining Phase II justification.

This 46-page issue is the largest and most comprehensive issue of NeuroPerspective ever produced, and includes:

1) An overview of the biology of Alzheimer's as it is currently conceptualized, albeit not yet validated.
2) A review of the many therapeutic strategies that have been employed, and that are currently under development.
3) The companies and programs that are in clinical, preclinical, and discovery stage. Over 215 therapeutic programs are covered in this review. They include variations on the secretase theme from Bristol Myers Squibb, EnVivo Pharmaceuticals, and Neurogenetic Pharmaceuticals; innovative approaches to disease progression from Merck/Alectos, Roche/reMYND, and NeuroPhage; and those with clinical data, such as EnVivo, Lundbeck, TauRx, and Prana.  
4) What is and is not clear from the sparse solanezumab results thus far disclosed, which have served as a Rorschach for those looking to have their preconceptions supported. With all due respect to the fever dreams of some Street analysts, these results are not going to be the basis for filing a NDA.
5) A sampling of novel biomarkers in development for AD, aimed at identifying markers for MCI/prodromal AD that will permit early intervention.
6) A spotlight review of AC Immune, one of the leaders in the development of antibodies for both amyloid and tau.
7) The positive results for EnVivo Pharma
'/>"/>

SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
2. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
3. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
4. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
6. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
9. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
10. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
11. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Peter Walter ... Biomedical Science for his pioneering work on how proteins ... components of a regulatory mechanism that cells use to ... Dr. Walter is a professor of biochemistry at the ... groundwork for treating a range of human diseases related ...
(Date:3/27/2015)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , today reported financial ... 31, 2014.  The Company reported a ... for the three months ended December 31, 2014.  This ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 PRC ... (CRO), announced today several management and executive appointments effective ... Chief Financial Officer (CFO) and member of the Board ... of Business Operations, and Sue Dowden will assume the ... co-founder and current Chief Operations Officer (COO), has been ...
(Date:3/26/2015)... March 26, 2015  BioNano Genomics, Inc., the leader ... Salyer as chief commercial officer. Salyer has more ... sales teams in life sciences. At BioNano, Salyer will ... a genome-mapping platform to assemble a comprehensive view of ... To date, 32 institutions located in the ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3
... , , COLUMBIA, Md., Sept. 8 ... that a panel of judges on the United States Court of ... appeal proceedings related to a patent infringement lawsuit between Martek and ... GmbH (collectively "Lonza"). The appeals involve Lonza,s U.S. sale and ...
... , PRINCETON, N.J., Sept. 8 Pharmasset, Inc. ... the Robert W. Baird & Co. Health Care Conference, Morgan ... Sciences Conference in New York, NY and the ThinkEquity G6 ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will ...
... , FORT LAUDERDALE, Fla., Sept. 8 ... in the region, launched an important joint event with the state,s ... gathered in Fort Lauderdale on August 27, to hear experts from ... of bio science and information technology. , , ...
Cached Biology Technology:Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 2Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 3Pharmasset to Present at Four Upcoming Investor Conferences 2Pharmasset to Present at Four Upcoming Investor Conferences 3South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 2South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 3
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... of Pennsylvania School of Medicine have clarified the mechanism ... problems, in multiple animal models. The findings offer the ... bypass this issue, as reported in the April 13 ... Journal of Clinical Investigation. , "Although these results are ...
... at an alarming rate throughout Britain's coast and rivers, ... crab, brought to Britain during the last century in ... populations are not monitored and controlled, say the study's ... upon Tyne carried out the first comprehensive modelling of ...
... from the Max Planck Institite for Biophysical Chemistry ... magnetic resonance spectroscopy (solid-state NMR) with special protein ... toxins combine and change in structure. This work ... high blood pressure and many other diseases connected ...
Cached Biology News:Therapeutic prospects beyond Vioxx 2Therapeutic prospects beyond Vioxx 3Exotic crab poised for widespread UK invasion 2Exotic crab poised for widespread UK invasion 3Unraveling the mysteries of poison 2
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Biology Products: